

**Hepatitis B Virus Progression  
in Relation to  
Viral Load, Genotypes, Quasispecies, Host Factors  
and its Effect on Outcome of Treatment**

*Essay*

*Submitted for Partial Fulfillment of  
Master Degree in Internal Medicine*

*By*

Ahmed Mohammed Abdel Fattah Mazen  
(M.B.B.ch)

*Under Supervision Of*

**Prof. Dr. Osama Abo El Fotoh El Sayed**

Professor of Internal Medicine  
Gastroenterology and Hepatology  
Faculty of Medicine  
Ain Shams University

**Assist. Prof. Dr. Essam Farid Mahdy**

Assistant Professor of Internal Medicine  
Gastroenterology and Hepatology  
Faculty of Medicine  
Ain Shams University

**Dr. Maha Mohsen Mohamed Kamal**

Lecturer of Internal Medicine  
Faculty of Medicine  
Ain Shams University

*Faculty of Medicine  
Ain Shams University  
2009*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا  
عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ  
{البقرة/ ٣٢}

# *Acknowledgments*

*He and will always be Allah who blessed my work and who sent me those who were of help.*

*Indeed, words do fail me when I come to express my deep respect to Professor Dr. Osama Abo El Fotoh El Said Professor of Internal Medicine, Gastroenterology and Hepatology Faculty of Medicine - Ain Shams University who gave me much of his time, effort, and many helpful comments, discussions and instructions. I learnt from him how to play an active role and to share in the world's scientific progress around us. Indeed, I was much impressed by his noble character, patience and sympathy.*

*I would like to express my deepest gratitude to Assist. Prof. Dr. Essam Farid Mahdy Assistant Professor of Gastroenterology and Hepatology Faculty of Medicine - Ain Shams University For his kind support, helpful comments, and continuous advice and encouragement.*

*I would like to thank so much Dr. Maha Mohsen Mohamed Kamal Lecturer of Internal Medicine Faculty of Medicine - Ain Shams University for her extra ordinary honest effort and comprehensive help.*

## CONTENTS

<b>Title</b>	<b>Page</b>
List of abbreviations	I
List of tables	III
List of figures	IV
Introduction	V
Aim of the work	VIII
<b>CHAPTER I : HBV Virology</b>	
1.1. Epidemiology	1
1.2. Structure of HBV	5
1.3. HBV Life Cycle	10
1.4. Molecular Pathogenesis	13
1.5. Natural History of Hepatitis B virus progression	15
1.6. Diagnosis of hepatitis B virus	29
1.7. Therapy of HBV	33
1.8. Prevention of HBV Infection	58
<b>CHAPTER II : FACTORS AFFECTING HBV PROGRESSION</b>	
<b>SECTION I : HEPATITIS B VIRAL FACTORS</b>	61
(A) Viral Load	61
(B) Genotypes	68
(C) HBV Quasispecies	80
(D) Other Viral Factors	94
<b>SECTION II : HOST FACTORS</b>	96
(I) Gender	96
(II) Age at infection	96
(III) Host Genetic Factors	103
(IV) Host Immune Factors.	105
(V) Other Host Factors	109
<i>Summary and Conclusion</i>	112
<i>Recommendations</i>	114
<i>References</i>	115
<i>Arabic Summary</i>	

**List Of Abbreviations**

**AASLD:** American Association for Study of Liver Diseases  
**ALP:** Alkaline phosphatase  
**ALT:** Alanine aminotransferase  
**Anti-HBc:** Hepatitis B core antibody  
**Anti-HBe:** Hepatitis B e antibody  
**Anti-HBs:** Hepatitis B surface antibody  
**AST:** Aspartate aminotransferase  
**cccDNA:** Covalently closed circular DNA  
**CTLs:** Cytotoxic T lymphocytes  
**DNA:** Deoxyribonucleic acid  
**ELISA:** Enzyme linked immunosorbant assay  
**g/dl:** Gram per deciliter  
**HBcAg:** Hepatitis B core antigen  
**HBeAg:** Hepatitis e antigen  
**HBIG:** Hepatitis B Immune Globulin  
**HBsAg:** Hepatitis B surface antigen  
**HBV:** Hepatitis B virus  
**HCC:** Hepatocellular carcinoma  
**HCV:** Hepatitis C virus  
**HDV:** Hepatitis Delta virus  
**HLA:** Human leukocyte antigen  
**IDUs:** Injecting Drug Users  
**Kd:** Kilo Dalton  
**LCF:** Liver cell failure  
**IU/ml:** International unit per milliliter  
**mg/dL:** Milligram per deciliter  
**MHC:** major histocompatibility complex  
**MIU:** Million international unit  
**ng:** Nanogram  
**NK:** Natural killer  
**PBMCs:** peripheral blood mononuclear cells  
**PCR:** Polymerase chain reaction  
**Pg:** Pico gram  
**RNA:** Ribonucleic acid  
**STD:** Sexually transmitted diseases  
**WHO:** World Health Organization  
 **$\alpha$ -INF:** Alpha interferon  
 **$\mu$ g:** Micro gram  
 **$\mu$ mol/L:** Micro mol per liter

---

## LIST OF ABBREVIATIONS

### The 20 L- $\alpha$ -Amino Acids ( Symbol And Name ) ( the monomer units of proteins )

- 1)     **A**     Alanine Ala [A]
- 2)     **C**     Cysteine Cys [C]
- 3)     **D**     Aspartic acid Asp [D]
- 4)     **E**     Glutamic acid Glu [E]
- 5)     **F**     Phenylalanine Phe [F]
- 6)     **G**     Glycine Gly [G]
- 7)     **H**     Histidine His [H]
- 8)     **I**     Isoleucine Ile [I]
- 9)     **K**     Lysine Lys [K]
- 10)    **L**     Leucine Leu [L]
- 11)    **M**     Methionine Met [M]
- 12)    **N**     Asparagine Asn [N]
- 13)    **P**     Proline Pro [P]
- 14)    **Q**     Glutamine Gln [Q]
- 15)    **R**     Arginine Arg [R]
- 16)    **S**     Serine Ser [S]
- 17)    **T**     Threonine Thr [T]
- 18)    **V**     Valine Val [V]
- 19)    **W**     Tryptophan Trp [W]
- 20)    **Y**     Tyrosine Tyr [Y]

## LIST OF TABLES

<b>TABLE</b>	<b>TITLE</b>	<b>PAGE</b>
<b>Table 1.1.</b>	Serological profiles of chronic hepatitis B virus infection	<b>18</b>
<b>Table 1.2.</b>	Evidence-based benefits of HCC treatments	<b>23</b>
<b>Table 1.3.</b>	Location and Terminology of Antiviral Resistant Mutations	<b>37</b>
<b>Table 1.4.</b>	Recommended doses of medications for Treating HBV	<b>41</b>
<b>Table 1.5.</b>	<b>Advantages and Disadvantages of NAs and Interferon as First Line Therapy for CHB</b>	<b>55</b>
<b>Table 2.1.</b>	HBV DNA levels predict risk of developing cirrhosis	<b>64</b>
<b>Table 2.2.</b>	HBV DNA levels predict risk of developing HCC	<b>65</b>
<b>Table 2.3.</b>	HBV Genotypes: Geographical Distribution and sequence characteristics.	<b>69</b>
<b>Table 2.4.</b>	Comparison of clinical and virologic differences between hepatitis B virus genotype B vs. C and A vs. D	<b>76</b>
<b>Table 2.5.</b>	Some features of viral quasispecies	<b>81</b>
<b>Table 2.6.</b>	Annual prevalent resistance rates for lamivudine, adefovir, entecavir, emtricitabine, and telbivudine.	<b>86</b>
<b>Table 2.7.</b>	Polymerase and envelope link	<b>90</b>

**LIST OF FIGURES**

<b>FIGURE</b>	<b>TITLE</b>	<b>PAGE</b>
<b>Fig.1.1.</b>	Hepatitis B surface antigen prevalence worldwide	<b>2</b>
<b>Fig.1.2</b>	Structure of the HBV particle.	<b>5</b>
<b>Fig.1.3</b>	HBV genome and open reading frames for the corresponding encoded proteins .	<b>5</b>
<b>Fig.1.4</b>	Model for the protein structure of small HBsAg.	<b>6</b>
<b>Fig.1.5.</b>	Expression of core protein and HBeAg.	<b>8</b>
<b>Fig.1.6.</b>	Schematic representation of HBV polymerase	<b>9</b>
<b>Fig.1.7.</b>	Hepatitis B virus replication cycle.	<b>11</b>
<b>Fig.1.8.</b>	Epsilon .	<b>12</b>
<b>Fig.1.9.</b>	HBV Pathogenesis	<b>13</b>
<b>Fig.1.10.</b>	Immune phases of Hepatitis B virus progression	<b>15</b>
<b>Fig.1.11.</b>	The differences of Keffe and AASLD algorithms for treatment of HbeAg +ve patients	<b>39</b>
<b>Fig.1.12.</b>	The differences of Keffe and AASLD algorithms for treatment of HbeAg -ve patients.	<b>40</b>
<b>Fig.1.13.</b>	Rates of antiviral resistance for four therapies of chronic hepatitis B.	<b>43</b>
<b>Fig.2.1.</b>	Baseline HBV DNA Level and Relative Risk of Cirrhosis.	<b>64</b>
<b>Fig.2.2.</b>	Baseline HBV DNA Level and Cumulative Incidence of HCC Entire Cohort.	<b>66</b>
<b>Fig.2.3.</b>	Expression of core protein and HBeAg.	<b>70</b>
<b>Fig.2.4.</b>	The nucleotide sequence and predicted secondary structure of the HBV encapsidation signal of genotype A.	<b>71</b>
<b>Fig.2.5.</b>	Precore and core promoter mutants	<b>83</b>
<b>Fig.2.6.</b>	The MHR (amino acids 100 to 160) and the “a” determinant (amino acids 124 to 147).	<b>84</b>
<b>Fig.2.7.</b>	HBV polymerase drug-resistant mutants.	<b>87</b>
<b>Fig.2.8.</b>	The proposed pathways for the L-nucleosides (LMV, LdT), acyclic phosphonates, and shared and multidrug resistance (MDR) linked to the eight codons associated with nucleos(t)ide analogues (NA) drug failure	<b>88</b>
<b>Fig.2.9.</b>	Polymerase-envelope overlap in the HBV genome highlighting that drug-resistant changes in polymerase can cause potentially important changes in HBsAg with all the NA currently available.	<b>90</b>
<b>Fig.2.10.</b>	Impact of age on HBV Progression.	<b>96</b>



## INTRODUCTION

Chronic infection with hepatitis B virus (HBV) currently affects about 400 million people, particularly in developing countries, and it is estimated that worldwide over 200,000 and 300,000 chronic HBV carriers die each year from cirrhosis and hepatocellular carcinoma (HCC), respectively (*Perz et al., 2006*).

HBV is highly endemic in sub-Saharan Africa, China and South-East Asia. It is also highly endemic in the Mediterranean basin and it is present at significant levels in most industrialized countries (*Lee et al., 1998*).

Exposure to HBV can cause a broad spectrum in clinical manifestations of human HBV infection that may differ even among family members. The clinical manifestations range from a clinically asymptomatic condition to those with overt pathology that can be acute hepatitis or chronic liver disease (*Thoi et al., 2000*). The majority of adults with primary HBV infection (90-95%) can successfully clear the virus and only 5-10% of adults become chronic HBV earners. Among the chronically infected individuals, 20-30% leads to liver cirrhosis and about 5% develop hepatocellular carcinoma through a long-term disease progression. On the other hands, more than 90% develop chronic infection in the perinatally transmitted cases. The reasons for this variation in the natural history of HBV infection are not fully understood, but viral and immunological factors (viral load, viral mutations, and host immunity) could play important roles in modulating both the antiviral immune response and host susceptibility to HBV (*Choi, 2004*).

Men seem to be more prone to developing CHB than women, although the reasons for this gender difference are unclear (*Ryder and Beckingham, 2001b*).

The risk of progression to chronic HBV infection is inversely proportional to the age at infection. Up to 50 to 90% of neonates and infants born to HBeAg positive mothers become HBV carriers, as compared to 20 to 30 % among children infected between the age of 1-5

years, and less than 5% among immunocompetent adults (*Thoi et al., 2003*).

High viral load predicts progression of liver disease, cirrhosis, cirrhosis-related complications, and HCC independent of HBeAg, ALT, and cirrhosis (with a threshold of risk starting to rise at an HBV DNA concentration somewhere between  $10^4$  and  $10^5$  copies/ml.) (*Iloeje et al., 2006 and Chen et al., 2006*).

The symptoms and complications of HBV infection arise from liver damage. However, HBV does not itself directly damage hepatocytes, as it is not directly cytopathic. Instead, the liver damage and symptoms characteristic of HBV seem to arise from the immune system's attempts to remove the infection. Several types of white blood cell (cytotoxic and natural killer T-cells) fight the virus by killing infected cells, but the immune system also produces chemical messengers (cytokines), such as interferons, which appear to have antiviral effects inhibiting viral replication; reducing proliferation of viruses to infect new cells; and modulating the immune response to the infection (*Ganem and Prince, 2004*).

The importance of the immune system in HBV progression means that immunosuppressed people often show only mild liver damage, despite having high levels of the virus in their blood. Similarly, patients infected early in life are generally asymptomatic and show little liver damage for several decades despite a heavy viral load, as the immune system initially tolerates the infection and therefore causes no damage. Unfortunately this can change in later life, with a sudden activation of the disease process, in the main due to a mutation of HBV (*Ganem and Prince, 2004*).

HBV isolates have been classified into 9 different serotypes according to the antigenic determinants of their HBsAg. However, the classification of HBV by serologic subtype is not rational because a single point mutation at the S gene may result in a change in subtype. Therefore, according to the molecular evolutionary analysis of the genomic DNA

sequence, HBV strains isolated in various countries are classified into 8 genotypes: genotypes A to H (*Arauz-Ruiz et al., 2002*).

HBV is a variable virus, due to the intrinsic properties of the HBV DNA polymerase, the enzyme that ensures viral replication. HBV, like other viruses with error-prone polymerases, such as HIV, hepatitis C virus (HCV) and poliovirus, has a "quasispecies" distribution in infected individuals (*Gunther et al., 1999*).

This means that HBV circulates as a complex mixture of genetically distinct but closely related variants that are in equilibrium at a given time point of infection in a given replicative environment. The quasispecies distribution of HBV is characterized by the coexistence of different viral populations in various proportions. Variant populations are continuously selected by the changing environment in which the virus replicates during human infection. The quasispecies distribution of HBV implies that any newly generated mutation conferring a selective advantage to the virus in a given replicative environment will allow the corresponding viral population to overtake the other variants, following a classical Darwinian evolutionary process (*Domingo and Gomez, 2007*).

Apart from direct biological effects of viral variants, there is a growing consensus that the host immune response, especially the virus-specific T cell response, is the key determinant influencing the course of disease and the onset of liver disease (*Zhou et al., 2003*).



**AIM OF THE WORK**

## **AIM OF THE WORK**

Studying an update of factors affecting hepatitis B virus progression including viral and host factors.



# **CHAPTER I**

## **HBV Virology**

---

# Hepatitis B Virus

## 1.1. Epidemiology

### (A) Mode of Transmission

HBV is transmitted by percutaneous and mucosal exposure to infectious blood or body fluids. The highest concentrations of virus are found in blood; however, only semen and saliva have been demonstrated to be infectious. HBV remains viable and infectious in the environment for at least 7 days and can be present in high concentrations on inanimate objects, even in the absence of visible blood (*Cindy et al., 2008*).

Persons with chronic HBV infection are the major source of new infections, and the primary routes of HBV transmission are sexual contact, percutaneous exposure to infectious body fluids (such as occurs through needle sharing by injecting drug users (IDUs) or needlestick injuries in health-care settings), perinatal exposure to an infected mother, and prolonged, close personal contact with an infected person (e.g., via contact with exudates from dermatologic lesions, contact with contaminated surfaces, or sharing toothbrushes or razors), as occurs in household contact. No evidence exists of transmission of HBV by casual contact in the workplace, and transmission occurs rarely in childcare settings. Few cases have been reported in which health-care workers have transmitted infection to patients, particularly since implementation of standard universal infection control precautions (*Cindy et al., 2008*).

### (B) HBV worldwide

Worldwide, chronic infection with hepatitis B virus (HBV) currently affects about 400 million people, particularly in developing countries, and it is estimated that 500,000 to 1,000,000 persons die annually of HBV-related liver disease (*Mahoney, 2008*).

The prevalence of HBV infection varies markedly in different parts of the world. Approximately 45% of the world's population live in areas where the prevalence of chronic HBV infection is high (8% or more of the population is HBsAg positive), 43% live in areas where the prevalence is moderate (2 to 7% of the population is HBsAg positive),